Back to Newsroom

Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis

NORWOOD, MA — (Marketwired) — 10/20/15 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration (“FDA”) has designated as a Fast Track development program and granted Orphan Drug Designation to the Company’s investigational new drug Resunab™ for the treatment ofcystic fibrosis (“CF”).

Click here to read more